leadf
logo-loader
viewInnoCan Pharma

Innocan Pharma says Mackie Research sales group issues Enterprise report on its potential clinical, licensing and commercial catalysts

Analyst Toby Ma highlighted the Israeli company’s potential clinical, licensing and commercial catalysts

InnoCan Pharma - Innocan Pharma Corporation says Mackie Research Capital Corporation's institutional sales group has issued an updated Enterprise report on its potential clinical, licensing and commercial catalysts
Innocan is developing a revolutionary injectable CBD delivery system

InnoCan Pharma Corporation (CSE:INNO) announced Thursday that Mackie Research Capital Corporation's institutional sales group has issued an updated Enterprise report on the company.

The Enterprise report provides valuable insight into companies that embody value-add for investors, have distinguished themselves among their peers and are bringing innovative and creative ideas into action.

READ: InnoCan Pharma collaborating with Recipharm in Israel to synthesize and analyze cannabinoid-loaded exosomes

In a statement, Innocan said Mackie Research analyst Toby Ma highlighted the Israeli company’s potential clinical, licensing and commercial catalysts:

  • Pre-clinical data of CLX-CBD loaded exosomes to treat COVID-19 is expected in 9 to 12 months.
  • Innocan is looking to out-license CLX and the liposome product before Phase 1 trials.
  • Its CBD-based consumer health products are expected to be launched in several international markets in the fourth quarter of 2020. The company is looking to sign more regional distribution agreements going forward.

The Enterprise report is based upon general comments with no ratings and should not be construed to be a research report, Innocan said.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

 

 

 

 

 

 

Quick facts: InnoCan Pharma

Price: 0.28 CAD

CSE:INNO
Market: CSE
Market Cap: $49.1 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Innocan Pharma received U.S. FDA approval for their over the counter CBD...

Innocan Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive Vancouver with news the company has just received FDA approval in the United States for their patent-pending CBD Relief &GO pain relief collection. Bincovich talks about the collection and when they would...

on 07/20/2020

2 min read